Jun Pang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7193019/publications.pdf

Version: 2024-02-01

59	1,158	18	32
papers	citations	h-index	g-index
61	61	61	2106
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer. British Journal of Radiology, 2022, 95, 20210191.	2.2	7
2	Smart nanocarriers as therapeutic platforms for bladder cancer. Nano Research, 2022, 15, 2157-2176.	10.4	7
3	Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma. BMC Cancer, 2022, 22, 83.	2.6	8
4	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. BMC Cancer, 2022, 22, 177.	2.6	2
5	Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma. Cell Death and Disease, 2022, 13, 443.	6.3	7
6	Smart dual responsive nanocarriers with reactive oxygen species amplification assisted synergistic chemotherapy against prostate cancer. Journal of Colloid and Interface Science, 2022, 622, 789-803.	9.4	6
7	MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. Computational and Structural Biotechnology Journal, 2021, 19, 4941-4953.	4.1	9
8	Mutated SPOP E3 Ligase Promotes $17\hat{l}^2$ HSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Cancer Research, 2021, 81, 3593-3606.	0.9	18
9	Dual pH- and Glutathione-Responsive CO ₂ -Generating Nanodrug Delivery System for Contrast-Enhanced Ultrasonography and Therapy of Prostate Cancer. ACS Applied Materials & Samp; Interfaces, 2021, 13, 12899-12911.	8.0	8
10	CDK7 blockade suppresses superâ€enhancerâ€associated oncogenes in bladder cancer. Cellular Oncology (Dordrecht), 2021, 44, 871-887.	4.4	6
11	Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 659442.	2.8	3
12	Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy. Materials Science and Engineering C, 2021, 123, 111956.	7. 3	21
13	Systematic Chromatin Accessibility Analysis Based on Different Immunological Subtypes of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 575425.	2.8	6
14	CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. Cell Death and Disease, 2021, 12, 740.	6.3	19
15	Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. Frontiers in Oncology, 2021, 11, 764119.	2.8	20
16	A polymer‑calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy. Journal of Controlled Release, 2021, 340, 259-270.	9.9	13
17	Fundamentals and applications of nanoparticles for ultrasoundâ€based imaging and therapy. Nano Select, 2020, 1, 263-284.	3.7	9
18	A Meta-Analysis of Glasgow Prognostic Score and Modified Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 1541.	2.8	24

#	Article	IF	CITATIONS
19	Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Frontiers in Oncology, 2020, 10, 586192.	2.8	4
20	<p>MiR-301a Promotes Cell Proliferation by Repressing PTEN in Renal Cell Carcinoma</p> . Cancer Management and Research, 2020, Volume 12, 4309-4320.	1.9	14
21	Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer and Prostatic Diseases, 2020, 23, 220-231.	3.9	39
22	Associations of Mental Health and Personal Preventive Measure Compliance With Exposure to COVID-19 Information During Work Resumption Following the COVID-19 Outbreak in China: Cross-Sectional Survey Study. Journal of Medical Internet Research, 2020, 22, e22596.	4.3	63
23	Prepubertal-type teratoma in a postpubertal patient: case report and review of literature. International Journal of Clinical and Experimental Pathology, 2020, 13, 2407-2411.	0.5	0
24	The Effect of Single-port Transvesical Laparoscopic Radical Prostatectomy on Erectile Function and Urinary Continence Compared to Intrafascial Endoscopic Extraperitoneal Radical Prostatectomy. Urology Journal, 2020, 17, 592-596.	0.4	1
25	Screening of pH-responsive long-circulating polysaccharide–drug conjugate nanocarriers for antitumor applications. Journal of Materials Chemistry B, 2019, 7, 251-264.	5.8	42
26	Cyclinâ€dependent kinase 7 inhibitor THZ1 in cancer therapy. Chronic Diseases and Translational Medicine, 2019, 5, 155-169.	1.2	14
27	Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives. Current Topics in Medicinal Chemistry, 2019, 19, 57-73.	2.1	33
28	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European Urology, 2018, 73, 322-339.	1.9	130
29	Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer. OncoTargets and Therapy, 2018, Volume 11, 1077-1086.	2.0	10
30	Calpainâ€2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NFâ€₽B/DNMT1 signaling pathway. Prostate, 2018, 78, 682-690.	2.3	15
31	Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate. Cancer Cell International, 2018, 18, 3.	4.1	1
32	Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients. Asian Journal of Andrology, 2018, 20, 56.	1.6	6
33	Prospective Study of CRMP4Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases. Journal of the National Cancer Institute, 2017, 109, djw282.	6.3	12
34	MP99-04 TRUNCATED-CRMP4 BY CALPAIN-2 SUPPRESSES CRMP4 TO PROMOTE METASTASIS OF PROSTATE CANCER VIA PROMOTER METHYLATION THROUGH E2F1/NF-?B/DNMT1 SIGNALING. Journal of Urology, 2017, 197, .	0.4	0
35	P110β Inhibition Reduces Histone H3K4 Diâ€Methylation in Prostate Cancer. Prostate, 2017, 77, 299-308.	2.3	12
36	Subrenal capsule grafting technology in human cancer modeling and translational cancer research. Differentiation, 2016, 91, 15-19.	1.9	24

#	Article	IF	CITATIONS
37	ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer. Oncology Letters, 2016, 11, 2532-2538.	1.8	3
38	Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up. Clinical Genitourinary Cancer, 2016, 14, e321-e327.	1.9	4
39	AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension. Translational Andrology and Urology, 2016, 5, AB201-AB201.	1.4	0
40	Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. Oncotarget, 2015, 6, 10030-10044.	1.8	35
41	Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 1227-33.	1.3	8
42	Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution. Journal of Cancer Research and Clinical Oncology, 2013, 139, 871-878.	2.5	8
43	Singleâ€port transvesical laparoscopic radical prostatectomy for organâ€confined prostate cancer: technique and outcomes. BJU International, 2013, 112, 944-952.	2.5	14
44	GW24-e3520â€Association of cardiovascular disease and erectile dysfunction: share the same risk factors?. Heart, 2013, 99, A130.2-A130.	2.9	0
45	<i>ERG</i> Rearrangement for Predicting Subsequent Cancer Diagnosis in High-Grade Prostatic Intraepithelial Neoplasia and Lymph Node Metastasis. Clinical Cancer Research, 2012, 18, 4163-4172.	7.0	34
46	Investigation of Optimal Prostate Biopsy Schemes for Chinese Patients with Different Clinical Characteristics. Urologia Internationalis, 2012, 89, 425-432.	1.3	4
47	Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy. International Journal of Nanomedicine, 2012, 7, 4037.	6.7	40
48	Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly ($\hat{l}\mu$ -caprolactone)/hydroxyapatite microspheres. Journal of Materials Science: Materials in Medicine, 2011, 22, 547-555.	3.6	25
49	Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-κB in prostate cancer cells. Molecular Biology Reports, 2010, 37, 1849-1855.	2.3	30
50	Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. Journal of Controlled Release, 2010, 147, 278-288.	9.9	74
51	Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene, 2010, 29, 4555-4566.	5.9	55
52	Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer. Journal of Molecular Diagnostics, 2010, 12, 718-724.	2.8	25
53	Profiling Protein Markers Associated with Lymph Node Metastasis in Prostate Cancer by DIGE-based Proteomics Analysis. Journal of Proteome Research, 2010, 9, 216-226.	3.7	92
54	Cyclooxygenase-2 Expression Is Associated with Vascular Endothelial Growth Factor-C and Lymph Node Metastases in Human Prostate Cancer. Archives of Medical Research, 2009, 40, 268-275.	3.3	28

#	Article	IF	CITATIONS
55	Toll-like receptor 9 agonists promote IL-8 and TGF- \hat{l}^2 1 production via activation of nuclear factor \hat{l}^2 B in PC-3 cells. Cancer Genetics and Cytogenetics, 2009, 192, 60-67.	1.0	34
56	Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 26-32.	1.6	14
57	Enhanced Antitumor Effects by the Coculture of Allotumor RNA-Pulsed Dendritic Cells with Autologous Cytokine-Induced Killer Cells on Hormone-Refractory Prostate Cancer. Cancer Investigation, 2007, 25, 527-534.	1.3	1
58	Proteomic analysis of rat penile tissue in a model of erectile dysfunction after radical prostatectomy. BJU International, 2007, 99, 1500-1505.	2.5	7
59	Proteomic analysis of rat penile tissue in a model of erectile dysfunction after radical prostatectomy. BJU International, 2007, 99, 1500-1505.	2.5	3